Crohn’s and colitis denials in California external review
Humira, Skyrizi, Stelara, Entyvio, Remicade, Rinvoq. Biologics are how moderate-to-severe IBD reaches remission — and they are exactly where pharmacy benefit managers apply step therapy, biosimilar switching, and dose limits. The California DMHC record publishes a separate cohort of external-review decisions for each IBD diagnosis label — the largest running to 347 decisions. Independent physician reviewers overturned the plan’s denial in 57.9–65.1% of them, depending on the diagnosis. Those historical results describe cases that reached this California program; they do not predict an individual appeal.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY
THESE FIGURES COUNT DECISIONS BY DIAGNOSIS — EVERY CASE ABOVE INVOLVED A CROHN’S, COLITIS, OR IBD DIAGNOSIS, WHATEVER TREATMENT WAS REQUESTED. THE DRUG-LEVEL TABLE BELOW IS A DIFFERENT CUT. EACH ROW BELOW IS ITS OWN COHORT OF PUBLISHED DECISIONS. ONE DECISION CAN NAME MORE THAN ONE OF THESE, SO THE ROWS OVERLAP AND MUST NOT BE ADDED TOGETHER — WE PUBLISH NO COMBINED TOTAL, BECAUSE THE DEDUPLICATED SET-UNION FIGURE IS NOT IN THE SOURCE AGGREGATES.
The record, drug by drug
| Drug | FDA-approved for | Decisions | Overturned |
|---|---|---|---|
| Skyrizi | Crohn's disease (adults) | 49 | 91.8% |
| Stelara | Crohn's disease (adults) | 57 | 80.7% |
| Entyvio | Moderately to severely active ulcerative colitis (adults) | 27 | 96.3% |
| Rinvoq | Moderately to severely active Crohn's disease in adults with inadequate response or intolerance to one or more TNF blockers | 28 | 82.1% |
| Humira | Crohn's disease (adults and children 6 and older) | 51 | 72.5% |
| Remicade | Crohn's disease, including fistulizing disease (adults and children 6 and older) | 36 | 61.1% |
| Adalimumab | See Humira | 35 | 68.6% |
| Stelara 90 Mg Every Four Weeks | See Stelara | 12 | 100% |
Why IBD biologic denials happen
These are among the most expensive drugs plans pay for, taken indefinitely, by patients who need them to stay in remission. That combination produces a recurring set of denial patterns — none of them, notably, a claim that the drug doesn’t work.
Step therapy — “fail the preferred agent first”
A common pattern. Formularies may require conventional therapy (steroids, immunomodulators) or a specific TNF blocker before newer mechanisms. The gastroenterologist's selection rationale — infection history, prior biologic failure, disease phenotype — supplies the patient-specific evidence an exception reviewer needs.
Biosimilar and non-medical switching
Adalimumab, infliximab, and ustekinumab all have FDA-approved biosimilars now — ustekinumab's include an interchangeable one — and formularies increasingly cover only a preferred product. For stable patients this is the fight: the plan is un-approving therapy that is working, for contracting reasons. Response history and switch-risk documentation carry the appeal.
Dose escalation and interval shortening denied
IBD dosing is sometimes intensified based on therapeutic drug monitoring and disease activity. Plans may deny the extra doses as quantity-limit violations or 'not medically necessary.' Objective monitoring data — drug levels, antibodies, calprotectin, CRP — gives the reviewer a patient-specific record for the requested regimen.
Site-of-care restrictions on infusions
Remicade and Entyvio infusions get steered from hospital outpatient departments to cheaper sites or home infusion; claims at the 'wrong' site are denied. Reaction history and monitoring needs are the exception grounds.
Continuation denied on plan or formulary change
New plan year, new employer, new PBM — and suddenly the biologic that induced remission needs prior authorization it can't get. Continuity of care is the argument: interrupting stable maintenance therapy in IBD risks flare, hospitalization, and loss of response to the drug itself.
Indication and documentation gaps
Approvals turn on chart-documented disease severity and prior-treatment history. Denials cite what the prior-auth request didn't include — colonoscopy findings, failed-agent details — far more often than any clinical dispute. The appeal supplies the record.
The sequencing game — and how the label cuts through it
Many IBD formularies use drug sequencing: which biologic the plan wants used first, second, third. Knowing where your prescription sits in that sequence tells you what the appeal must prove.
- TNF blockers first (Humira, Remicade, their biosimilars): usually the plan-preferred starting point. Denials here are mostly documentation and product-choice fights, not mechanism fights.
- Newer mechanisms (Skyrizi, Stelara, Entyvio): commonly placed behind a TNF blocker. The exception case is the prescriber’s mechanism rationale — gut-selectivity for infection-risk patients, IL-23 for TNF non-responders — and the California record reports that Skyrizi denials for Crohn’s disease were overturned 80% of the time in published decisions, and Entyvio denials for ulcerative colitis 100%.
- Post-TNF options (Rinvoq): here the FDA label itself requires prior TNF-blocker failure — so the step-therapy requirement and the label point the same direction, and the appeal is usually just precise documentation of that TNF history.
In the selected published decisions, a detailed prescriber rationale is a recurring part of the record. When that documentation is absent, the plan’s criteria may be left unrebutted. The source decisions remain case-specific.
Your fastest lever: the formulary exception process
Marketplace coverage and Medicare Part D provide formulary exception processes with decision clocks tied to a prescriber’s supporting statement; urgent employer-plan claims use a different framework. The exact deadline and next review step depend on the plan. Ask the plan whether the denial should be filed as a formulary or quantity-limit exception, then verify the controlling deadline. Full detail: prescription-drug denials, decoded.
The documentation that decides these cases
Overturned IBD decisions share a complete record. Before filing, assemble:
- The denial letter and the plan's clinical criteria for the drug (request them in writing — you are entitled to them).
- Diagnosis and severity documentation: colonoscopy/endoscopy findings, imaging, and disease-activity scores where charted.
- Objective markers: fecal calprotectin, CRP, and — for dose-escalation fights — therapeutic drug monitoring results (drug levels, antibody status).
- The complete prior-treatment log: every conventional agent and biologic tried, with doses, duration, outcome, and side effects.
- For switch denials: response history on the current product and any infusion-reaction or immunogenicity history.
- A gastroenterologist letter that walks the plan's criteria point by point, states the FDA-approved indication, and gives the sequencing rationale for this specific agent.
If the internal appeal fails: external review
Every number on this page comes from California DMHC external review, generally after the plan’s internal appeal process. Other jurisdictions and federal plan programs use different reviewers, eligibility rules, deadlines, and remedies; some plans are outside state external-review authority. Check your appeal rights by plan type and state.
Related reading: prescription-drug denials · “not medically necessary” denials · Crohn’s disease denial outcomes · ulcerative colitis denial outcomes · all treatments
IBD biologic denial FAQ
Step-therapy rules and exceptions depend on the plan and jurisdiction. Many plans provide an exception process in which a prescriber can document prior failures, contraindications, infection or malignancy history, or the clinical reason for a specific mechanism. Check the denial notice and plan criteria for the applicable deadline and required statement.
For a new start, plans generally may prefer their contracted product. For a patient stable in remission, the switch itself is a clinical decision: document your response history, any infusion-reaction or immunogenicity history, and have your prescriber state the risk of interrupting working therapy. Continuity-of-care arguments and formulary exception requests are the standard path, and denials of stable patients are among the most frequently reversed.
Dose escalation and interval shortening are routine in IBD care, often guided by therapeutic drug monitoring. Attach the objective data — drug levels, antibody status, inflammatory markers, disease activity — and file it as a formulary/quantity-limit exception with the prescriber's statement. This converts an argument into a data submission, which is exactly what independent reviewers respond to.
All six drugs on this page carry FDA approvals for Crohn's disease, ulcerative colitis, or both. A denial calling an on-label prescription experimental must be tied to something specific — and dose intensification based on monitoring is dosing judgment, not research. Demand the exact criteria and evidence basis; external reviewers apply current clinical evidence, not the plan's policy language.
Pharmacy exception clocks are measured in hours, not weeks: 72 hours standard and 24 hours expedited under the ACA marketplace rule and Medicare Part D (where the clock runs from your prescriber's supporting statement). Urgent ERISA claims are 72 hours. If your health is deteriorating, say the word 'expedited' explicitly, in writing.
You may be eligible for an independent external review, but the reviewer, deadlines, eligibility rules, and effect of the decision depend on your plan type and jurisdiction. The statistics on this page are limited to eligible cases completed through California DMHC's Independent Medical Review program.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY